OBJECTIVES: A major limitation of transcatheter aortic valve implantation (TAVI) is that its long-term outcomes are still unknown. The purpose of this study was to evaluate survival up to 5 years after implantation and to identify predictors of follow-up mortality in a large cohort of patients who underwent exclusively a transapical TAVI procedure.
INTRODUCTION
Eleven years ago, transcatheter aortic valve implantation (TAVI) was introduced into clinical practice as an alternative treatment option for aortic valve stenosis [1] . In the past 3 years, much effort has been put into the analysis of mid-term outcomes following TAVI procedures [2, 3] . However, long-term survival remains unclear. Recently, two reports from pioneering centres in this field focusing on 4-and 5-year outcomes in a very limited number of patients have been published [4, 5] .
The purpose of this study was to evaluate survival up to 5 years and to identify predictors of follow-up mortality in a large cohort of patients who underwent a transapical TAVI procedure exclusively. This study is an update on our preliminary report in this field [6] .
MATERIALS AND METHODS

Study design
This study was a retrospective, single-centre, observational cohort study of prospectively and retrospectively collected data. Without exception, all 730 consecutive patients who underwent a planned transapical TAVI procedure at our institution between 16 April 2008 and 1 August 2013 were included in the study. All patients completed at least the 30-day follow-up period. The Institutional Review Board at our institution approved this study and all patients or their representatives gave informed consent.
consensus. Although the arithmetic risk profile was considered only one among other selection criteria, 625 patients (85.6%) presented with a logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) of ≥15%, a Society of Thoracic Surgeons predicted operative mortality (STS PROM score) of ≥10% or a EuroSCORE II of ≥10%. Patients with low arithmetic risk values were only accepted for TAVI because of characteristics associated with higher risk for conventional surgery that were not adequately reflected in the risk models used. From the beginning of the study we followed a 'no exclusion policy' [7] , whereby patients with a very high risk profile, very advanced comorbidity status or cardiogenic shock were not excluded. This policy is still in place today. The whole institutional process of patient selection, inclusion and exclusion criteria as well as the diagnostic work-up and the selection of the access site have been described in detail in previous publications [6] [7] [8] and summarized in our "institutional clinical policies" as part of our structured training program [9] . During the study period, 425 patients underwent TAVI with vascular access at our institution. The preference given to the transapical access within the study cohort was based on our previously described institutional criteria [6] .
The baseline characteristics of all 730 patients are given in Table 1 . The cohort consisted of 439 females (60.1%) and 291 males (39.9%) with a median age of 80.1 years (interquartile range [IQR] , 75.3-84.4 years; range, 28.9-98.9 years). Forty patients (5.5%) were in cardiogenic shock. The mean logistic EuroSCORE was 35.0 ± 21.9%; the median logistic EuroSCORE was 28.8% (IQR, 18.9-48.2%; range 2.0-96.7%). The mean EuroSCORE II was 16.2 ± 16.2%; the median EuroSCORE II was 10.0% (IQR, 5.2-21.3%; range 0.8-95.1%). The mean STS PROM score was 14.0 ± 11.8%; the median STS PROM score was 10.4% (IQR, 6.1-17.8%; range 1.2-89.5%).
Implantation procedure
According to our structured institutional training programme, all TAVI procedures were performed in a standardized manner by our permanent TAVI team [8] . Transapical TAVI was performed in the hybrid operating theatre using a principal surgical technique [10] with some modifications [11] . [7, 12] .
Anticoagulation and antiplatelet therapy
The strategy of postoperative anticoagulation and antiplatelet medication adapted during the study period. According to the manufacturer's recommendation for the previous THV type of the Sapien prosthesis, aspirin (100 mg per day permanently) and clopidogrel (75 mg per day for 6 months) were given. Only in the case of bleeding complications or need for anticoagulation therapy with vitamin-K-antagonists did we waive the clopidogrel therapy. In cases of simultaneous percutaneous coronary intervention with drug eluting stent(s), clopidogrel was given for 12 months. After introduction of the XT type of the Sapien prosthesis (for which the manufacturer is now referring to general guidelines), the decision about antiplatelet regime and anticoagulation therapy was made on an individual basis. The following parameters were taken into consideration: (i) the presence of atrial fibrillation, (ii) the presence of other indications for phenprocoumon or warfarin therapy, (iii) simultaneous or recent percutaneous coronary intervention and the type of the implanted stent and (iv) the occurrence or history of bleeding complications. A standard protocol based on general guidelines was created by members of the TAVI team. This protocol is available on all wards of the hospital. If a patient was on clopidogrel before the TAVI procedure, transapical TAVI was performed without interruption of the clopidogrel administration.
Follow-up
The follow-up regarding death or survival was 100%. Official information regarding death was also obtained from the state administrative office. For all patients domiciled in Germany, information was obtained from the German Register of Residents. All patients domiciled in foreign countries were contacted via telephone, email or letter. 
RESULTS
Procedural outcome
A balloon-expandable prosthesis was implanted in all patients. [7] , valve deployment was performed with shortduration elective use of cardiopulmonary bypass in 42 (5.8%) patients. In 8 (1.1%) patients, conversion to surgical aortic valve implantation after deployment of the balloon-expandable prosthesis was necessary due to rupture of the device landing zone or coronary artery obstruction. Valve migration to the left ventricle after implantation of the prosthesis in the desired position was observed in 1 (0.1%) patient with hypoplasia of the aortic root after congenital heart surgery and chest radiation during childhood with porcelain aorta.
Redilatation was performed in 55 (7.5%) patients and/or a second prosthesis was implanted in 16 (2.2%) patients. At the end of the procedure, there was no regurgitation in 417 (57.1%) patients, trace (i.e. less than Grade I) regurgitation in 167 (22.9%) patients, mild (i.e. Grade I and less than Grade II) regurgitation in 140 (19.2%) patients and moderate (i.e. Grade II) regurgitation in 6 (0.8%) patients. There was no severe (i.e. greater than Grade II) regurgitation and no conversion to surgery because of untreatable regurgitation.
Thirty-day outcomes
The overall 30-day mortality rate was 4.5%; 33 patients died during the first 30 days after the TAVI procedure. Excluding all 40 patients in cardiogenic shock, the 30-day mortality rate was 3.9%; 27 of 690 patients died during the first 30 days. Aspects related to 30-day outcomes and complication rates according to the VARC-2 criteria are summarized in Table 2 . Preoperative, intra-and postprocedural factors found to be predictive (P < 0.05) of early mortality in the univariable and multivariable analysis are given in Table 3 .
Overall outcomes
The overall survival rates at 1, 2, 3, 4 and 5 years were 79.6 ± 1.6, 70.5 ± 1.9, 60.3 ± 2.3, 51.6 ± 3.0 and 41.4 ± 4.4%, respectively. The Kaplan-Meier survival function is shown in Fig. 1 . Excluding all 40 patients in cardiogenic shock, the survival rates at 1, 2, 3, 4 and 5 years were 81.7 ± 1.5, 72.3 ± 1.9, 62.0 ± 2.4, 52.9 ± 3.1 and 42.4 ± 4.6%, respectively. Patients without cardiogenic shock showed significantly (P < 0.001) better survival than patients in cardiogenic shock. The Kaplan-Meier survival functions are shown in Fig. 2 . The grade of post-procedural regurgitation was not found to be a significant predictor of follow-up mortality (hazard ratio [HR] = 1.22, 95% confidence interval [95% CI]: 0.92-1.61, P = 0.162). All significant (P < 0.05) predictors of overall follow-up mortality in the univariable and multivariable analysis are given in Table 4 .
Outcomes in quartiles of different arithmetic risk profile
Based on EuroSCORE II quartiles, four equal groups (n low EuroSCORE II = 183, n intermediate EuroSCORE II = 182, n high EuroSCORE II = 183, n very high EuroSCORE II = 182) of different arithmetic risk profile were defined: low arithmetic risk (EuroSCORE II ≤ 5%); intermediate arithmetic risk (EuroSCORE II 5-10%); high arithmetic risk (EuroSCORE II 10-21%); very high arithmetic risk (EuroSCORE II >21%). In the low-arithmetic-risk group, the survival rates at 1, 2, 3, 4 and 5 years were 88.1 ± 2.5, 81.1 ± 3.2, 74.2 ± 4.0, 62.0 ± 5.8 and 58.3 ± 6.5%, respectively. Survival was significantly better in patients of the low and intermediate arithmetic risk group compared with the patients at high risk (low vs high, P < 0.001; intermediate vs high, P = 0.001). Survival was significantly worst in the very high-risk group (high vs very high; P = 0.014). The KaplanMeier survival functions are shown in Fig. 3 .
Isolated long-term outcomes
Among the first 145 consecutive patients who underwent TAVI at least 4 years prior to the end of the observation period, there were 136 survivors of the 30-day postoperative interval. Within this subgroup of 136 patients, the survival rates at 1, 2, 3, 4 and 5 years were 81.6 ± 3.3, 66.9 ± 4.0, 57.2 ± 4.3, 48.2 ± 4.3 and 38.6 ± 4.9%, respectively. In the multivariable analysis for this subgroup, the following predictors of the follow-up mortality were identified: NYHA class (HR = 2.50, 95% CI: 1.56-4.02, P < 0.001), chronic atrial fibrillation (HR = 2.32, 95% CI: 1.41-3.80, P = 0.001), serum creatinine level (HR = 1.53, 95% CI: 1.23-1.90, P < 0.001), systolic pulmonary pressure of >50 mmHg (HR = 1.64, 95% CI: 1.01-2.68, P = 0.046) and age (HR = 1.03, 95% CI: 1.00-1.06, P = 0.036).
Freedom from reoperation on the aortic valve Eleven (1.5%) patients underwent reintervention or reoperation on the aortic valve during follow-up. Two (0.3%) patients underwent a second transapical TAVI procedure because of severe central regurgitation of unknown origin in one patient and deformation of the prosthesis frame after chest compression in the other. Nine patients (1.2%) underwent surgical aortic valve replacement. The indication and intraoperative causes for reoperation were: prosthetic aortic valve endocarditis in 3 (0.4%) patients, progressive paravalvular regurgitation in 3 (0.4%) patients, valve degeneration and transvalvular regurgitation in 1 (0.1%) patient and valve thrombosis in 2 (0.3%) patients who had undergone a TAVI as a valve-in-valve procedure. The freedom from reintervention or reoperation on the prosthesis was 95.7 ± 1.9% at 5 years (Fig. 4) . 
DISCUSSION
The mean life expectancy for the standard German population at the age of 80 years is given to be 9.13 years for women and 7.77 years for men [14] . Our cohort of TAVI patients with a median age of 80.1 years fails to reach these survival rates. However, patients with EuroSCORE II <10% achieved a 5-year survival rate of 55 and 58%, respectively. These subgroups approximated to the survival pattern of the standard population, indicating that the comorbidity profile and the preoperative status are relevant determinants of long-term outcomes. Based on this context and as a continuation of our previous reports on mid-term results [6] [7] [8] , our study demonstrates favourable long-term outcomes after TAVI procedure.
TAVI versus surgical aortic valve replacement in terms of mortality rates
Surgical aortic valve replacement remains the first-line therapy and gold standard in the treatment of aortic valve stenosis [15] . Based on the STS database, the early mortality rates for patients at age 75-85 is 3.3-4.9% [16] . In our patients with an IQR range of age from 75 to 84 years, the 30-day survival rates of 4.5% (overall) and 3.9% (excluding cardiogenic shock patients) correspond to this result. Within the STS data set, an observed-to-expected mortality ratio of 0.8 for the year 2006 is given [16] . Based on a mean STS PROM score of 14.0% in our study cohort, we observed an overall observed-to-expected mortality ratio of 0.3, indicating that similar early mortality rates compared with surgical aortic valve replacement were achieved by TAVI in patients who presented with a distinctly higher risk profile. Thourani et al. [17] showed an in-hospital mortality rate of 16.4% in 159 patients with a mean STS PROM score of 16.3%, whereby only patients with an STS PROM score of 10% or greater were included in their study. In comparison with their study, our study cohort enclosed 368 patients (50.4%) with STS PROM score of >10%. The median STS PROM score in this sub-cohort was 21.6 ± 12.2 (range, 10.1-89.5%). These values are distinctly higher compared with those in the study cohort of Thourani et al. [17] . Including cardiogenic shock patients (n = 33), the 30-day mortality rate in our sub-cohort of all 368 patients with an STS PROM score of >10 was 5.7% (21/368 patients). The 1-year survival rate was 73 ± 2% including cardiogenic shock patients. To compare outcomes in numbers even in the case of different selection criteria and a significantly higher risk profile in our study cohort: Thourani et al. [17] reported an in-hospital mortality rate of 15-18% and a 1-year survival rate of 67-75%. Neglecting the fact of short-term advantages by TAVI strategy, Thourani et al.
[17] described a 5-year survival rate of 47.4 (38-55% with worst outcome in the age group 70-79 years), indicating a favourable long-term outcome after successful surgical aortic valve replacement even in patients with a higher risk profile. One may conclude from this that, regardless of the choice of treatment (surgical versus transcatheter) and after survival of the early postoperative period, the long-term outcomes after both methods are equal [18] . However, achieving device success without relevant paravalvular leakage might be one prerequisite.
Regurgitation after TAVI-even in its mild forms-is known to have a negative impact on mid-term survival with an HR of 2.1 [3] to 3.8 [19] . Our study failed to demonstrate a significant influence of overall grade of post-procedural regurgitation on outcomes. This may be related to the fact that severe regurgitation was absent in our study cohort and moderate regurgitation was only accepted as an exception [20] .
Our study cohort patients with lower arithmetic risk profile represent a highly selected group. The true surgical risk for these patients is not adequately mirrored in their calculated risk. Therefore, their long-term outcomes may not be compared with those of classical surgical cohorts only by means of matched risk scores.
Predictors of follow-up and long-term mortality
Recently, the experiences of pioneering Canadian centres regarding 4-and 5-year follow-up after TAVI have become available to the TAVI community [4, 5] . Rodés-Cabau et al. [4] published a multicentre study of 339 patients-including 177 patients after transapical TAVI-with a 4-year survival rate of 43%. They identified chronic atrial fibrillation (HR: 1.39), chronic obstructive pulmonary disease (HR: 1.84), reduced glomerular filtration rate (HR: 1.12 for each decrease of 10 ml/min) and frailty (HR: 1.41) as significant predictors of cumulative late mortality in multivariable analysis. Furthermore, they differentiated between the transfemoral access site (where solely pulmonary hypertension was significantly predictive) and the transapical approach (where chronic obstructive pulmonary disease, reduced glomerular filtration rate and frailty were significantly predictive). Excluding 8 patients with unsuccessful TAVI and 15 non-survivors of the 30-day period, Toggweiler et al. [5] published a single-centre study of 5-year outcomes in 88 remaining patients-including 24 patients with transapical TAVIand a 5-year survival rate of 35%. They identified chronic obstructive pulmonary disease (HR: 2.17), left ventricular ejection fraction <50% (HR: 1.38), moderate or severe paravalvular regurgitation (HR: 2.98), vascular complication (HR: 1.63) and bleeding complication (HR 1.25) as significant predictors of follow-up mortality in multivariable analysis. These pioneering centres have made a valuable contribution to validating long-term outcomes. Our results underscore their preliminary conclusions. Similar to both Canadian studies, we confirmed impaired kidney function and atrial fibrillation as significant predictors of overall follow-up mortality and additionally pulmonary hypertension as a significant predictor of isolated long-term mortality in our multivariable analyses. Furthermore, advanced pulmonary disease was found to have a significant negative impact on survival at least in our univariable analysis. However, we add two more predictors: cardiogenic shock and acute kidney injury as procedure-related complications. Patients in cardiogenic shock were not considered in the Canadian trials. From our viewpoint, TAVI potentially promises to eliminate the cause of cardiogenic shock without the additional trauma of cardioplegic arrest. Despite the higher follow-up mortality rate, our previous report in this field verified that TAVI is much more than an ultima ratio attempt for this group of critical patients with otherwise known dismal outcomes [21] . The second predictor-we would like to add-is any kind of severe procedure-related complication. The post-procedural occurrence of acute kidney injury is associated with known tubular cell necrosis. In addition, it involves a complicated and long-lasting procedural course with haemodynamic instability over a longer time period, severe bleeding or the need for high amounts of contrast agent. From our viewpoint, any imperfection of the TAVI procedure in patients of very advanced age and high risk may be followed by a cascade of dramatic and life-threatening consequences. Although the management of severe intraprocedural complications may be challenging compared with conventional surgery [12] , they were found to be rare in our cohort. We observed lower rates of permanent stroke, revision for bleeding or renal failure in comparison with cohorts with higher risk profiles who underwent surgical aortic valve replacement [17, 18] . TAVI is becoming a reliable and safe alternative treatment for such patients. The main advantage of TAVI over surgery is its associated shorter period of convalescence due to less surgical trauma.
Freedom from structural valve deterioration
Long-term durability has been shown for bioprosthetic valves used for surgical aortic valve replacement. In commonly used porcine valves, a 20-year actuarial freedom from reoperation for structural valve deterioration of 73% in patients at the age of 65 years or older has been described [22] . Similarly for pericardial bioprostheses, a 15-year actuarial freedom from reoperation for structural valve deterioration of 82.3% (for all age groups) has been shown [23] . The long-term durability of transcatheter valves in vivo still remains unclear. Toggweiler et al. [5] described moderate forms of prosthetic valve failure in 3.4% at 5 years. Only 1/88 patients underwent surgical valve replacement because of infective endocarditis 5 months after the procedure. Rodés-Cabau et al. [4] found 2 patients within their study cohort of 339 patients who underwent surgical valve replacement because of endocarditis 7 and 13 months after TAVI. Furthermore, they describe a slight decrease in valve area at 2 years without any significant further changes in the 4-year follow-up. No significant changes in the grade of residual regurgitation were found. Both Canadian studies confirm good long-term durability even in earlier generations of balloon-expandable prostheses. In terms of paravalvular regurgitation, their findings indicate that the result achieved immediately after implantation is decisive; there is no evidence to suggest that regurgitation will disappear if left untreated after valve deployment. Our study protocol focused on structural valve deterioration requiring redo surgery on the aortic valve prosthesis. We confirmed good long-term durability in terms of freedom from reintervention or reoperation. Endocarditis as the underlying reason for reoperation was found in 3 patients; 2 of them survived an episode of septicaemia (urosepsis and pneumonia) after TAVI, and the third presented with possibly unrecognized prosthetic endocarditis and underwent a valve-in-valve procedure. Taking each individual post-procedural course into account, we did not find any evidence of susceptibility of the transcatheter valve to endocarditis. The opposite is our clinical impression; the transcatheter valve seems to be very robust against infection. Symptomatic progressive paravalvular regurgitation was very rare in our study cohort. In all 3 patients who underwent transcatheter valve explantation, we identified an unfavourable anatomy for TAVI, such as bicuspid morphology, very asymmetric calcification of the device landing zone or too large an annulus. This observation represents a disadvantage of the TAVI procedure compared with surgical aortic valve replacement. Any uncertainty in terms of unfavourable anatomy of the device landing zone needs to be eliminated in the future by improving preoperative screening and valve size selection. The rate of valve thrombosis after valve-in-valve procedures needs to be clarified in larger studies. But this needs to be done before this concept is broadened.
Transapical versus transfemoral approach
As we previously stated [6, 7] , we consider that transapical and transfemoral approaches are two different therapeutic options for treating the same clinical problem, namely severe aortic stenosis in patients with increased risk from conventional procedures. Both procedures are competitive not only with conservative therapy or standard aortic valve replacement but also between themselves (transfemoral versus transapical versus transaxillary versus transaortic). The best treatment option evaluated in each patient should be chosen. In our institution, we are able to offer all these options. Our 'TAVI team' uses all approaches of TAVI, and currently we can perform implantation in the manner that is best for the patient. This question is often raised: What are the criteria in deciding between a transapical and a transfemoral approach? The simplest way is to decide according to the condition of the vascular access (state, presence or absence of peripheral arterial disease, calcifications and diameter of the arteries). If the status of iliacofemoral arteries allows it, transfemoral implantation should be performed as the primary option. Transapical implantation is a more difficult technique than transfemoral implantation and needs a longer learning curve [7, 8] . In order to achieve excellent expertise in both techniques, we first used the transapical method of valve implantation (except in patients who had larger aortic valve annuli). In contrast, transapical implantation is a very simple and direct procedure. It has several advantages over the retrograde transvascular route. The transapical approach is independent of the degree of the patient's peripheral arterial disease. Furthermore, the advancing of the wire in an antegrade direction through the valve is very easy, rapid and simple in comparison with the retrograde approach used with transfemoral implantation. It may reduce or eliminate cerebral embolization during this phase of the procedure. We also expect a lower rate of neurological complications because the danger of embolization during manipulation in the aortic arch is reduced or eliminated by the transapical route. However, our main reason for the exclusive use of the transapical approach at the beginning of our project is the excellent and safe possibility of precise deployment of the new valve in the desired position by applying our modified valve implantation technique (Berlin addition [11] ). The inflation of the balloon during valve deployment is performed slowly, not instantly, as described in the principal technique [10] , allowing the valve position to be corrected if necessary. We expect that in the future the transfemoral method will be performed more frequently. It could be the primary way of implantation if the results in terms of procedural success (e.g. low rate of neurological complications) could be matched to those of the transapical method. The advantage of the transfemoral method is that it is a much easier way to implant a valve on an awake patient. The main indication for a transapical aortic valve implantation is of course severe atherosclerotic peripheral disease in the inguinal and the iliac regions. It is important that the same team is educated to use all approaches of TAVI (transapical and transvascular) to be able to decide intraoperatively and to perform the means of implantation that is best for the patient [6] .
Study limitations
This study has two major limitations. (i) The study is based only on TAVI and is further limited to the transapical access site. A comprehensive and randomized trial of all treatment options and all access sites would require the power of a multicentre study and is still lacking. On the other hand, a major benefit of our study design is the consistent data set and a large number of patients treated with one identical strategy by a permanent team. (ii) The long-term follow-up in this study is limited to survival/mortality and structural valve deterioration requiring redo intervention/ surgery. A comprehensive long-term follow-up of all possible complications, their clinical assessment and relationship to the procedure and a meticulous evaluation of patients' neurocognitive function and quality of life were not possible. To answer these questions comprehensively, further studies are necessary.
Conclusions
We identified three main causes of follow-up mortality. (i) Comorbidity: After elimination of aortic valve stenosis, patients die from non-cardiac comorbidities (such as kidney or lung disease). End-stage cardiac comorbidity not directly related to aortic valve stenosis (atrial fibrillation, coronary artery disease or right-sided heart failure and pulmonary hypertension) is another relevant aspect of follow-up mortality. The comorbidity profile is well expressed in standard surgical risk estimators, such as EuroSCORE or STS PROM score models. (ii) Advanced stage of heart failure related to aortic valve stenosis: patients who presented in an advanced stage of heart failure (higher NYHA class, higher NT-pro-BNP levels, failing ventricles or cardiogenic shock) have a dramatically worse outcome compared with those who were treated in earlier stages of aortic valve disease. (iii) Procedure-related complications: the occurrence of complications related to the TAVI procedure ( periprocedural myocardial infarction, acute kidney injury or major access-related complications) has a negative impact on survival after TAVI. This aspect dominates mainly early mortality, but is also verifiable in the long term.
APPENDIX. CONFERENCE DISSCUSSION
Dr J. Kempfert (Bad Nauheim, Germany): I think that your data set is of unmatched value, especially from a surgical perspective, as I am not aware of another TA first selection data set and, clearly, the good outcomes that we see here prove the potential for a transapical procedure in a highly experienced centre. I have three questions for you.
The first is, what do you think is the main reason for the often inferior results, especially in lower volume centres, in regard to TA versus transfemoral access, or, in other words, do you think there is a specific learning curve associated with the transapical procedure which might not be so much the case in transfemoral cases?
Secondly, if you compare your data to the literature results, it is striking; you have not presented the data here but it is in your manuscript. Out of these 700 cases, I think it is all SAPIEN, your leak rate, relevant leaks 2+ or more, is 0.6% only. So all other patients, more than 99% of patients, had either none or a mild leak only. I have never seen such good results in regard to the SAPIEN. Maybe you can elaborate a little bit on that and maybe there is a secret trick that you can share with us.
Third, as we still lack long-term data, maybe you could mention if you have recorded the pressure gradients over time, so that we can perhaps see some or even no hints of early valve degeneration.
Dr Unbehaun: First of all, I am convinced that it takes a little more time to become familiar with all the steps involved in transapical TAVI. Transfemoral access may indeed be a little bit easier to learn. We established an institutional educational programme that ensures that every member of the team is trained to perform the procedure in the same standardized manner, and this helped a lot to keep the results stable in terms of mortality. I believe the transapical approach is a very good one: it is safe and easy; we like using the transapical access route. We are not a transfemoral first centre but we are also not a transapical first centre. So the decision as to which access site is selected is made on an individual basis.
The second question deals with aortic regurgitation. Indeed, we don't want the patient to leave the OR with relevant regurgitation. We all know that the hazard ratio for follow-up mortality is close to 4 in patients with moderate or severe regurgitation. For that reason we are relatively aggressive in doing re-ballooning or putting in another valve. The rate for putting in another valve is 2.2% and that is our intention. We prefer slow, stepwise inflation. I think this helps a lot in finding the right position for the valve and you can deploy it precisely. Indeed, we see a low grade of post-procedural regurgitation in this group.
Regarding long-term follow-up of echo data, we do not have the whole echocardiographic follow-up for all of these 1,200 patients. They are followed in outpatient clinics. However, 11 patients in this group underwent reintervention or reoperation on the aortic valve during follow-up. In three patients, for instance, endocarditis was the reason for reintervention or reoperation. So a total of 1.5% underwent these redo procedures, and the actuarial five-year freedom from reintervention or reoperation on the aortic valve is 96% for this cohort. I think the SAPIEN valve used here is a durable valve.
Dr Kempfert: I don't want to be mean, but I really want to come back to that paravalvular leak rate, because, again, if you compare your data, re-ballooning I think was 7%, if I recall it correctly from the manuscript, and valve-in-valve 2%, so it is pretty much comparable to SOURCE. Still, 99.4% with no relevant leak for SAPIEN is an unmatched result. We have never seen this before.
Dr Unbehaun: The way we analyse regurgitation is as follows. After putting in the valve, we perform a detailed echo. We use angiography, applying 20 ml of contrast agent, of course, and my colleague, Dr Kukucka, is working on another method. We use contrast echo, which is a very sensitive method for detecting even very thin regurgitation jets. We don't want to accept paravalvular leakage, and in those few cases where we did accept moderate leakage, we did so as an exception. But from the standpoint of a surgeon, I think we should avoid all forms of leakage.
Dr V. Bapat (London, UK): I think you should acknowledge the fact that we don't have control of the morphology of the aortic valve, so if there are eccentric calcifications, as one of the previous presenters showed in some examples, you are still going to get moderate leak however much you post dilate.
I just want to clarify. You are neither a transfemoral first centre nor a transapical first centre. So how do you choose? If a patient comes to you and he has good transfemoral arteries, what do you do? What is it based on? Dr Unbehaun: Our philosophy stems from a more scientific point of view. All types of TAVI are competitive with conventional surgery, but all of these TAVI access types are competitive between themselves. To the best of my knowledge, there is no study that has shown that one access site is superior to another. This would require the power of a multicentre study. Of course, we look at the status of the iliac or femoral vessels, we look at the calcium load within the aortic arch, we also look at the distances of the coronaries to the annulus, we look at the calcium load within the leaflets, we look at the calcium load below the leaflets, and all of these facts are incorporated into the decision process.
In our team, even the surgeons do the transfemoral cases and our cardiologists are becoming more and more experienced in transapical procedures. So even if the patient comes with clear iliac or femoral vessels, sometimes the cardiologists say, well, let's do it transapically; they want to get the experience, and the most important thing is that the final result is good.
Dr Bapat: And I just want to ask you, what are the 2.1% conventional surgeries you did with transapical? There were 2% of patients who had conventional operations. What were they?
Dr Unbehaun: The first patient in whom we decided to combine TAVI and conventional surgery was a patient with an occluded LAD and porcelain aorta. So we did a LIMA to LAD OPCAB. And there were several other procedures, in patients with a high-grade tricuspid regurgitation, and we were convinced that this would have a negative impact on follow-up. So we decided to go ahead with combined tricuspid valve repair.
Dr Bapat: That is interesting, because you did a full sternotomy and then you did a transapical.
Dr Unbehaun: We did a full sternotomy, or combined left-sided mini-anterior thoracotomy for TAVI and right-sided thoracotomy for tricuspid valve repair.
